Recombinant Human IL-5 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0276NP
BL-0276NP: Greater than 95% as determined by SEC-HPLC. (Regularly tested)
BL-0276NP: Greater than 95% as determined by SEC-HPLC. (Regularly tested)

Recombinant Human IL-5 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-0276NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Interleukin-5 is produced by our Mammalian expression system and the target gene encoding Ile20-Ser134 is expressed with a 6His tag at the C-terminus.
Accession P05113
Synonym Interleukin-5; IL-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; IL5
Gene Background IL-5 is expressed in eosinophils, NK cells, TC2 CD8+ T cells, mast cells, CD45+ CD4+ T cells, gamma delta T cells and IL-1 beta activated endothelial cells. IL-5 acts as a growth and differentiation factor for both B cells and eosinophils. Relative to B cells, IL-5 appears to induce the differentiation of activated conventional B-2 cells into Ig-secreting cells. In addition, it induces the growth of B-1 progenitors as well as IgM production by B-1 cells.IL-5 appears to perform a number of functions on eosinophils. These include the down modulation of Mac-1,the upregulation of receptors for IgA and IgG,the stimulation of lipid mediator (leukotriene C4 and PAF) secretion and the induction of granule release.IL-5 also promotes the growth and differentiation of eosinophils.
Molecular Mass 14.2 KDa
Apmol Mass 20 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by SEC-HPLC. (Regularly tested)
Biological Activity Biologically active. Please contact us to obtain bioactivity data.
Reconstitution Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Factor that induces terminal differentiation of late-developing B-cells to immunoglobulin secreting cells.
Subcellular Location Secreted.
Protein Families IL-5 family
Database References

Gene Functions References

  1. IL-5 is expressed intrathecally in tick-borne encephalitis, but its pathogenetic role remains unclear. PMID: 29602685
  2. eosinophilia in FE is secondary to dysregulation of IL-5 production in PBMC (and their component subsets). PMID: 28226398
  3. Data indicate that interleukin-5 (IL-5) was that only serum cytokines show statistical significance between severe chronic obstructive pulmonary disease (COPD) and controls. PMID: 28398462
  4. Serum IL-5 and IL-13 are reliable biomarkers for the blood eosinophilia asthma phenotype. PMID: 27060452
  5. Longitudinal co-variations between inflammatory cytokines, lung function and patient reported outcomes in patients with asthma PMID: 28915273
  6. Obesity alters the lung neutrophil infiltration to enhance breast cancer metastasis through IL5 and GM-CSF. PMID: 28737771
  7. simvastatin was demonstrated to inhibit IL-5-induced CCR3 expression and chemotaxis of eosinophils mediated via the mevalonate pathway. PMID: 27275740
  8. Interleukin-5/-targeted treatments offer promises to patients with eosinophilic respiratory disorders; review PMID: 26859368
  9. Data indicate that interleukin 5 (IL-5)-associated single nucleotide polymorphisms (SNPs) were not associated with carotid intima-media thickness. PMID: 26821299
  10. Post-liver transplant patients with food allergy showed a unique cytokine profile in response to various stimuli, with extremely elevated IL-5, low IL-10 secretion. PMID: 26282695
  11. Production of IL-5 in response to both extract and the Bet v1-derived peptide mix strongly suggested that T cells were a major source of IL-5. PMID: 25817862
  12. It has been shown in this study that the level of IL-5, one of the markers of eosinophilic inflammation, is higher in EBC of children with atopic asthma than in those with nonatopic asthma. PMID: 25937050
  13. IL-5 may be part of protective mechanisms operating in early atherosclerosis, at least in women PMID: 25587992
  14. Results showed that PAX2 expression is significantly overexpressed in esophageal squamous cell carcinoma tissues and IL-5 is identified as PAX2's effector for metastasis. PMID: 25613757
  15. Subsequent IL-5-stimulated signaling. PMID: 25121926
  16. increased levels in recurrent versus nonrecurrent rhinosinusitis with nasal polyps at the moment of the first surgery PMID: 24980230
  17. HDM-specific IL-5 responses at age 3 years or later are the best measure of T cell function for predicting asthma at age 8 years. PMID: 24875149
  18. Fibrocytes studied were generated in vitro from PBMCs by culturing in the presence of platelet derived growth factors and stimulated by IL-33. Fibrocytes constitutively expressed IL-13 and IL-5, which was augmented by stimulation with IL-33. PMID: 24822215
  19. Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. PMID: 24530098
  20. Patients with the 'IL-5, IL-17A, IL-25-high' airway inflammatory pattern are often uncontrolled asthmatics, despite daily treatment. PMID: 23957336
  21. These unexpected results provide a theoretical basis for the therapeutic targeting of IL-5 in bladder cancer PMID: 23770289
  22. In activated eosinophils ligation of Siglec-8 leads to ROS-dependent enhancement of IL-5-induced ERK phosphorylation, which results in a novel mode of biochemically regulated eosinophil cell death. PMID: 23684072
  23. When patients were classified according to sputum IgE levels, it appeared that IL-5, IL-6, IL-17 and TNF-alpha sputum supernatant levels were raised in the "IgE high" asthmatics when compared to "IgE low" asthmatics PMID: 23555579
  24. alpha(M)beta(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. PMID: 23306834
  25. Type I interferon (IFN)-dependent inhibition of T cell-derived IL-5 is mediated by IFN-alpha acting directly on activated T cells. PMID: 23382558
  26. Strong IL-5 production was detected in response to peptides from several of the previously undescribed proteins of grass pollen. PMID: 23401558
  27. Topical steroid treatment may suppress IL-5 gene expression, and steroids may inhibit eosinophil functions in nasal polyps. PMID: 15835818
  28. Elevated expression of inflammatory cytokines (IL-5, IL-20, and IL-28A) is associated with bladder cancer development. PMID: 22962576
  29. binding of IL-5 to IL-5Ralpha plays a critical role in MMP-9 expression, which may be involved in the migration of bladder cancer. PMID: 22710862
  30. The study reports the crystal structure of dimeric IL-5 in complex with the IL5RA extracellular domains. PMID: 22528658
  31. Elevated levels of IL-5, which uses the neural plasticity-related RAS GTPase-ERK pathway to mediate its actions in the central nervous system, could be one of the factors underlying the depression-related changes in CNS plasticity. PMID: 22230487
  32. elevated levels in induced sputum from patients with asthma and allergic rhinitis PMID: 22186238
  33. REVIEW: Interleukin-5 and IL-5 receptor in health and disease PMID: 21986312
  34. The structure demonstrates that for steric reasons, homodimeric IL-5 can bind only one receptor molecule, even though two equivalent receptor-binding sites exist. PMID: 22153509
  35. There is no correlation between the eosinophilic infiltration and the expression of IL-5 in lung cancer tissues. PMID: 21609545
  36. Transplantation of human mesenchymal stem cells suppresses middle cerebral artery occlusion (MCAO) focal ischemia-induced inflammation, possibly through expression of fractalkine and interleukin (IL)-5. PMID: 21168500
  37. results demonstrate that IL-5(+) and IL-5(-) Th2 cells, respectively, represent more and less highly differentiated Th2 cell subpopulations PMID: 21849680
  38. IL-5 may play a role in the early phase of acute pneumonia caused by the 2009 H1N1 virus in Japanese children. PMID: 21323726
  39. Activation of GATA-3 might be one of the mechanisms for induction of IL-5 expression in chronic rhinosinusitis. PMID: 17628972
  40. AP-1 may participate in the signal transduction of PKC-triggered expression of IL-5 in allergic rhinitis T lymphocytes. PMID: 17438848
  41. PPD-induced preferential secretion by PBMCs of Warao indigenous patients in Venezuela PMID: 20650294
  42. Functional polymorphisms in the genes encoding the Th2 cytokines Il-5, IL-6, and IL-13, are associated differently with the development and prognosis of autoimmune thyroid disease from each other. PMID: 21235536
  43. IL-5 and IL-8 are the key cytokines in the formation of nasal polyps. PMID: 16929824
  44. Suggest that IL-5 responses in cord blood samples were strongly related to the season of birth. PMID: 20825427
  45. promotes increased immunoglobulin M at the site of disease in leprosy PMID: 20561085
  46. Our study identifies CXCL10 and IL-5 as proteins differentiating complicated and uncomplicated plaques from human carotid arteries PMID: 20943047
  47. Sputum IL-5 was associated with a sputum eosinophilia. PMID: 19478474
  48. data indicate that ability to produce the type 2 cytokines IL-13 and IL-5 defines CD161(+) NK cells at intermediate stages of differentiation, and is lost upon terminal functional differentiation, concomitant with acquired ability to produce IFN-gamma PMID: 11830476
  49. CD4(+) T cells are the major source of IL-5 among CD3(+) lymphocytes in atopic asthmatic subjects, whereas in nonatopic asthmatic subjects CD8 (+) T cells as well as CD4(+) T cells contribute to the increased production of IL-5 PMID: 11842300
  50. By itself, IL5 increases nerve growth factor level in eosinophils, but in combination with immune complexes, significantly reduces eosinophil NGF levels. PMID: 11877300

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed